ArticleOphthalmology. Retina2025
Long-Term Effects of Anti-VEGF Therapy versus Panretinal Photocoagulation on Retinal Vessel Caliber in Eyes with Proliferative Diabetic Retinopathy.
Article in Ophthalmology. Retina, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Anti-vascular endothelial growth factor therapy for posterior segment diseases: Progress, challenges, and the road ahead.Indian journal of ophthalmology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeTo evaluate the long-term effects of ranibizumab compared with panretinal photocoagulation (PRP) on retinal vasculature in eyes with proliferative diabetic retinopathy (PDR).
designPost hoc analysis of DRCR Retina Network Protocol S randomized clinical trial.
participantsAdults with type 1 or 2 diabetes and PDR in at least 1 eye.
methodsIntegrative Vessel Analysis software was used to measure central retinal arteriolar equivalent (CRAE) and central retinal venular equivalent (CRVE) of vessels at 1 disc diameter from the optic nerve edge on fundus photographs at baseline, 2 and 5 years for study eyes randomized to ranibizumab or PRP treatment for PDR. Changes in CRAE and CRVE were analyzed using mixed linear regression models with multivariable adjustments.
main outcome measuresMean change in CRAE and CRVE from baseline to 2 and 5 years.
resultsData from 107 eyes (90 participants) in the ranibizumab (n = 48) and PRP group (n = 59) were analyzed. For the ranibizumab versus PRP groups, CRAE decreased by a mean of 2 versus 12 μm at 2 years (mean difference, 10 μm; 95% confidence interval [CI], 4-16; P = 0.003); and 9 versus 13 μm at 5 years (mean difference, 4 μm; 95% CI, -2 to 10; P = 0.22). Central retinal venular equivalent decreased by 14 versus 19 μm at 2 years (mean difference, 4 μm; 95% CI, -3 to 11; P = 0.26) and 18 versus 28 μm at 5 years (mean difference, 11 μm; 95% CI, 3-19; P = 0.01).
conclusionsIn patients with PDR, CRAE and CRVE decreased in both the ranibizumab and PRP groups at 5 years, but the rates of change before and after 2 years may be different. In this subset of eyes from Protocol S, the greater reduction in CRAE in the PRP group was statistically significant at 2 years but not at 5 years. For CRVE, the PRP group decreased more than the ranibizumab group, but the difference was statistically significant at 5 but not 2 years. Future research may investigate the underlying causes for retinal arteriolar and venular narrowing after treatment for PDR, and the possibility of an anatomic correlation with visual field loss. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.